Most Recent
The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.
Melbourne aged care provider St Basil's has been convicted and fined $150,000 for failing to provide a safe working environment for staff during the COVID-19 pandemic, when dozens of residents died.
A class action against Dr Daniel Lanzer and his clinic has won approval to allege that some doctors passed themselves off as plastic surgeons in social media posts, including some that included the terms #plasticsurgeon and #plasticsurgery.
Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.
Mayne Pharma has launched a bid for a $13.6 million gross sum costs order against US drug maker Cosette, after winning one of numerous legal challenges over the termination of a $672 million merger agreement.
Aged care provider Bupa can't challenge the dismissal of its bid for a quick win in a class action over the standard of care at its facilities, despite a court noting the case has "some curiosities".
Bayer and Teva have lost their challenge to Indian drug maker Cipla’s extension of its patent for an allergy medication, with IP Australia finding a failure to pay renewal fees on time was due to a genuine error.
A Melbourne gynaecologist faces a possible class action by women who claim they underwent unnecessary endometriosis surgeries.
ASX-listed Mayne Pharma has taken US drug maker Cosette to court seeking "substantial damages" over the termination of their $672 million merger.
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.